{"commentary":{"count":12,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":5,"youtube":4,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04420598\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DEBBRAH","nct_id":"NCT04420598","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=debbrah-nct04420598. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"DEBBRAH","arms":[{"description":"* Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.);\n* Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM;\n* Cohort 3: HER2-positive BC with progressing BMs after local treatment;\n* Cohort 4: HER2-low expressing BC with progressing BMs after local treatment;\n* Cohort 5: HER2-positive or HER2-low expressing BC with LMC.","label":"Trastuzumab deruxtecan (DS-8201a)","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2023-04-04","type":"ACTUAL"},"conditions":["Advanced Breast Cancer","HER2-positive Breast Cancer","Brain Metastases","Leptomeningeal Metastasis"],"enrollment":{"count":41,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"}],"last_update":"2025-06-24","lead_sponsor":"MedSIR","official_title":"Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan(DS-8201a) in Human Epidermal Growth Factor Receptor 2 HER2+ Advanced Breast Cancer With Brain Metastases and/or Leptomeningeal Carcinomatosis","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1)","timeFrame":"From baseline up to 16 weeks"},{"measure":"Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4)","timeFrame":"Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months."},{"measure":"Overall Survival in Cohort 5","timeFrame":"Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months."}],"references":[{"citation":"Vaz Batista M, Perez-Garcia JM, Garrigos L, Garcia-Saenz JA, Cortez P, Racca F, Blanch S, Ruiz-Borrego M, Fernandez-Ortega A, Fernandez-Abad M, Iranzo V, Gion M, Martrat G, Alcala-Lopez D, Perez-Escuredo J, Sampayo-Cordero M, Llombart-Cussac A, Braga S, Cortes J. The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med. 2025 Jan 10;6(1):100502. doi: 10.1016/j.medj.2024.08.001. Epub 2024 Sep 11.","pmid":"39265579","type":"DERIVED"},{"citation":"Vaz Batista M, Perez-Garcia JM, Cortez P, Garrigos L, Fernandez-Abad M, Gion M, Martinez-Bueno A, Saavedra C, Teruel I, Fernandez-Ortega A, Servitja S, Ruiz-Borrego M, de la Haba-Rodriguez J, Martrat G, Perez-Escuredo J, Alcala-Lopez D, Sampayo-Cordero M, Braga S, Cortes J, Llombart-Cussac A. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open. 2024 Sep;9(9):103699. doi: 10.1016/j.esmoop.2024.103699. Epub 2024 Sep 9.","pmid":"39255534","type":"DERIVED"}],"start_date":{"date":"2020-05-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease","url":"https://clinicaltrials.gov/study/NCT04420598"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/debbrah-nct04420598"}